Cargando…

Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma

Detalles Bibliográficos
Autores principales:	Khan, Abdullah M., Dvorak, Kiatlyn, Zhao, Qiuhong, Bumma, Naresh, Cottini, Francesca, Devarakonda, Srinivas, Umyarova, Elvira, Sharma, Nidhi, Benson, Don, Rosko, Ashley
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690893/ https://www.ncbi.nlm.nih.gov/pubmed/37439332 http://dx.doi.org/10.3324/haematol.2022.282521

Ejemplares similares

Racial differences as predictors of outcomes in young patients with multiple myeloma
por: Bao, Alicia, et al.
Publicado: (2022)

Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma
por: Bao, Alicia, et al.
Publicado: (2023)

Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma
por: Nunnelee, Jordan, et al.
Publicado: (2022)

Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience
por: Nunnelee, Jordan, et al.
Publicado: (2022)

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
por: Cottini, Francesca, et al.
Publicado: (2021)

Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma
por: Ozga, Michael, et al.
Publicado: (2023)

Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias
por: Braunstein, Zachary, et al.
Publicado: (2022)

Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant
por: Sigmund, Audrey M., et al.
Publicado: (2022)

Optimizing carfilzomib use in multiple myeloma treatment
por: Yoon, Sung-Soo
Publicado: (2019)

AL Amyloidosis: The Effect of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes
por: Ozga, Michael, et al.
Publicado: (2020)

AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival
por: Ozga, Michael, et al.
Publicado: (2020)

Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
por: Sharma, Nidhi, et al.
Publicado: (2021)

Targeted treatments for multiple myeloma: specific role of carfilzomib
por: Sugumar, Dhivya, et al.
Publicado: (2015)

Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation
por: Sharma, Nidhi, et al.
Publicado: (2021)

To be or not to be: the role of CD56 in multiple myeloma
por: Cottini, Francesca, et al.
Publicado: (2023)

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
por: Fostier, Karel, et al.
Publicado: (2012)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Role of Stem Cell Transplantation in Multiple Myeloma
por: Devarakonda, Srinivas, et al.
Publicado: (2021)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
por: Jain, Salvia, et al.
Publicado: (2011)

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
por: Jayaweera, Shansa Pranami E., et al.
Publicado: (2021)

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
por: Rosenthal, A, et al.
Publicado: (2016)

Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
por: Español, Ignacio, et al.
Publicado: (2017)

The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021)

Multidisciplinary Approach to Older Adults with Hematologic Malignancies—a Paradigm Shift
por: Wall, Sarah A., et al.
Publicado: (2022)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
por: Zhou, Xiang, et al.
Publicado: (2020)

Severe Right-Sided Heart Failure and Pulmonary Hypertension with Carfilzomib Treatment in Multiple Myeloma
por: Mathur, Pankaj, et al.
Publicado: (2020)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014)

Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells
por: Baranowska, Katarzyna, et al.
Publicado: (2016)

Carfilzomib boosted combination therapy for relapsed multiple myeloma
por: Steiner, Raphael E, et al.
Publicado: (2017)

Carfilzomib induced cardiotoxicity in a multiple myeloma patient
por: Méndez-Toro, Arnold, et al.
Publicado: (2020)

Carfilzomib-associated pulmonary arterial hypertension in multiple myeloma
por: Yang, Jenny Z., et al.
Publicado: (2021)

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
por: Jakubowiak, Andrzej J., et al.
Publicado: (2019)

Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review
por: Imtiaz, Hassaan, et al.
Publicado: (2021)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
por: Facon, Thierry, et al.
Publicado: (2022)

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
por: Badros, A Z, et al.
Publicado: (2013)

Acute Tubular Necrosis in a Patient With Myeloma Treated With Carfilzomib
por: Liberman, Vladimir, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qubvg9o4jt7nbk4ob0bqb2ru1c